BC Cancer Protocol Summary for Topical Mechlorethamine in Cutaneous T-cell Lymphoma

Protocol Code: LYMECHLOR
Tumour Group: Lymphoma
Contact Physician: Dr. Vincent Ho

ELIGIBILITY:

- Histology: cutaneous T-cell lymphoma (mycosis fungoides)
- Used as an alternate to carmustine
- Approval from Health Canada Special Access Program must be obtained for each patient.

TESTS:
None

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>mechlorethamine</td>
<td>160 mcg/g of gel</td>
<td>Apply a thin layer to lesions daily as directed by Skin Lymphoma Team member*</td>
</tr>
<tr>
<td>(chlormethine, LEDAGA®)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Apply to dry skin at least 4 hours before or 30 minutes after showering or washing. Apply gel immediately or within 30 minutes after removal from the refrigerator. Return tube to refrigerator immediately after each use.

Treatment will continue daily until 1 year after remission or as specified by Skin Lymphoma Team member
DOSE MODIFICATIONS:

<table>
<thead>
<tr>
<th>Cutaneous reaction</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any grade of skin ulceration or blistering, or moderately severe or severe dermatitis (eg. Marked skin redness with edema)</td>
<td>Stop until improvement, then restart at reduced frequency of once every 3 days.</td>
</tr>
<tr>
<td></td>
<td>If reintroduction is tolerated for at least 1 week, can increase frequency to every other day for at least 1 week then once daily application if tolerated</td>
</tr>
</tbody>
</table>

PRECAUTIONS:

1. **Cutaneous effects:** Skin irritation, erythema, rash, urticarial, skin-burning sensation, pain, pruritis, skin infections, skin ulceration, blistering, and skin hyperpigmentation are common.
2. **Women of childbearing potential:** not recommended if not using contraception.

Call tumour group chair at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

REFERENCES:

1. Recordati Rare Diseases Inc for Actelion Registration Ltd. Chlormethine (LEDAGA®) summary of product characteristics. London, United Kingdom; 3 March 2017.